Haptogen Announces Collaboration With DaeWoong Pharmaceuticals

Haptogen (Aberdeen, Scotland) announces the signing of a major new collaborative research agreement with leading Korean pharmaceutical company DaeWoong Pharmaceutical Company Ltd (Seoul, Korea). The long-term agreement will combine Haptogen's novel discovery approach with the formulation, manufacturing and marketing expertise of DaeWoong in order to progress the clinical development of a number of novel antibody therapeutics, targeted at important bacterial infections.

PR Scotland (http://www.pr-scotland.com/releases/050517-01.htm)